Merus NV
MRUS96.910USD
+0.010+0.01%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.35BMarket Cap
LossP/E TTM
More Details of Merus NV Company
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Merus NV Info
Ticker SymbolMRUS
Company nameMerus NV
IPO dateMay 19, 2016
CEOLundberg (Sven Ante)
Number of employees260
Security typeOrdinary Share
Fiscal year-endMay 19
AddressYalelaan 62
CityUTRECHT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code3584 CM
Phone310302538800
Websitehttps://merus.nl/
Ticker SymbolMRUS
IPO dateMay 19, 2016
CEOLundberg (Sven Ante)
Company Executives of Merus NV
Name
Name/Position
Position
Shareholding
Change
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-15.24%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paolo Pucci
Mr. Paolo Pucci
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-15.24%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 21
Updated: Sun, Dec 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Genmab A/S
94.86%
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
Shareholders
Shareholders
Proportion
Genmab A/S
94.86%
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
Shareholder Types
Shareholders
Proportion
Corporation
96.78%
Hedge Fund
40.76%
Investment Advisor/Hedge Fund
29.65%
Investment Advisor
15.32%
Research Firm
2.54%
Private Equity
1.78%
Venture Capital
1.47%
Bank and Trust
0.65%
Pension Fund
0.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
434
77.32M
101.98%
-5.60M
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Paradigm BioCapital Advisors LP
4.28M
5.65%
+727.89K
+20.48%
Jun 30, 2025
Avoro Capital Advisors LLC
3.16M
4.16%
+155.56K
+5.19%
Jun 30, 2025
Commodore Capital LP
3.52M
4.65%
-947.84K
-21.19%
Jun 30, 2025
Deerfield Management Company, L.P.
3.38M
4.47%
+210.70K
+6.64%
Jun 30, 2025
Westfield Capital Management Company, L.P.
2.04M
2.69%
+541.17K
+36.05%
Jun 30, 2025
RTW Investments L.P.
4.00M
5.28%
-168.84K
-4.05%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.22M
8.2%
+593.98K
+10.56%
Jun 30, 2025
Woodline Partners LP
1.54M
2.04%
+142.73K
+10.19%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
AltShares Merger Arbitrage ETF
3.3%
NYLI Merger Arbitrage ETF
3.1%
ALPS Medical Breakthroughs ETF
2.89%
Goldman Sachs Hedge Industry VIP ETF
2.75%
ProShares Merger ETF
2.74%
First Trust IPOX Europe Equity Opportunities ETF
2.61%
Tema Oncology ETF
2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
Harbor Health Care ETF
1.29%
AltShares Event-Driven ETF
1.23%
View more
AltShares Merger Arbitrage ETF
Proportion3.3%
NYLI Merger Arbitrage ETF
Proportion3.1%
ALPS Medical Breakthroughs ETF
Proportion2.89%
Goldman Sachs Hedge Industry VIP ETF
Proportion2.75%
ProShares Merger ETF
Proportion2.74%
First Trust IPOX Europe Equity Opportunities ETF
Proportion2.61%
Tema Oncology ETF
Proportion2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.4%
Harbor Health Care ETF
Proportion1.29%
AltShares Event-Driven ETF
Proportion1.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Merus NV?
The top five shareholders of Merus NV are:
Paradigm BioCapital Advisors LP holds 4.28M shares, accounting for 5.65% of the total shares.
Avoro Capital Advisors LLC holds 3.16M shares, accounting for 4.16% of the total shares.
Commodore Capital LP holds 3.52M shares, accounting for 4.65% of the total shares.
Deerfield Management Company, L.P. holds 3.38M shares, accounting for 4.47% of the total shares.
Westfield Capital Management Company, L.P. holds 2.04M shares, accounting for 2.69% of the total shares.
Paradigm BioCapital Advisors LP holds 4.28M shares, accounting for 5.65% of the total shares.
Avoro Capital Advisors LLC holds 3.16M shares, accounting for 4.16% of the total shares.
Commodore Capital LP holds 3.52M shares, accounting for 4.65% of the total shares.
Deerfield Management Company, L.P. holds 3.38M shares, accounting for 4.47% of the total shares.
Westfield Capital Management Company, L.P. holds 2.04M shares, accounting for 2.69% of the total shares.
What are the top three shareholder types of Merus NV?
The top three shareholder types of Merus NV are:
Genmab A/S
Paradigm BioCapital Advisors LP
Avoro Capital Advisors LLC
Genmab A/S
Paradigm BioCapital Advisors LP
Avoro Capital Advisors LLC
How many institutions hold shares of Merus NV (MRUS)?
As of 2025Q3, 434 institutions hold shares of Merus NV, with a combined market value of approximately 77.32M, accounting for 101.98% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.20%.
What is the biggest source of revenue for Merus NV?
In --, the -- business generated the highest revenue for Merus NV, amounting to -- and accounting for --% of total revenue.
